In bladder and prostate cancers, TP-mediated ERK activation phosphorylates the tumor suppressor protein forkhead box O3 (FOXO3), which is deacetylated by SIRT1, resulting in Skp2-mediated degradation. This evidence concerns the gene FOXO3 and prostate carcinoma.